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Open Forum Infectious Diseases
MAJOR ARTICLE
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Background. Chagas disease, caused by the parasite Trypanosoma cruzi, once considered a disease confined to Mexico, Central
America, and South America, is now an emerging global public health problem. An estimated 300 000 immigrants in the United
States are chronically infected with T. cruzi. However, awareness of Chagas disease among the medical community in the United
States is poor.
Methods. We review our experience managing 60 patients with Chagas disease in hospitals throughout the New York City metropolitan area and describe screening, clinical manifestations, EKG findings, imaging, and treatment.
Results. The most common country of origin of our patients was El Salvador (n = 24, 40%), and the most common detection
method was by routine blood donor screening (n = 21, 35%). Nearly half of the patients were asymptomatic (n = 29, 48%). Twentyseven patients were treated with either benznidazole or nifurtimox, of whom 7 did not complete therapy due to side effects or were
lost to follow-up. Ten patients had advanced heart failure requiring device implantation or organ transplantation.
Conclusions. Based on our experience, we recommend that targeted screening be used to identify at-risk, asymptomatic patients
before progression to clinical disease. Evaluation should include an electrocardiogram, echocardiogram, and chest x-ray, as well as
gastrointestinal imaging if relevant symptoms are present. Patients should be treated if appropriate, but providers should be aware of
adverse effects that may prevent patients from completing treatment.
Keywords. Chagas disease; heart transplant; New York City; nonendemic countries; Trypanosoma cruzi.
Chagas disease, caused by infection with the parasite
Trypanosoma cruzi, was once considered a disease confined to
poverty-stricken rural areas of Mexico, Central America, and
South America. The World Health Organization currently estimates that Chagas disease affects 6–7 million people and causes
10000 deaths each year [1, 2]. The countries with the highest
prevalence of Chagas disease are Bolivia, followed by Argentina,
Paraguay, Ecuador, El Salvador, and Guatemala [3]. In endemic
countries, most infections are acquired through vectorborne
transmission by triatomine bugs [4]. Oral transmission can
also occur when food or liquids contaminated with feces from
infected triatomine bugs are consumed and is associated with
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outbreaks of acute Chagas disease [5]. In nonendemic countries, T. cruzi can be transmitted through blood transfusion,
organ transplantation, congenitally from mother to child, and,
in rare cases, laboratory accidents [6, 7, 8, 9].
In the majority of cases, the acute phase of infection is never
identified, and affected individuals are diagnosed with the indeterminate form of chronic Chagas disease. Although most
chronically infected individuals are asymptomatic and unaware of their infection, they remain potential sources of transmission for the remainder of their life [10]. Roughly 20%–30%
of chronically infected individuals progress to develop cardiomyopathy, and 10%–15% develop gastrointestinal involvement [11, 12]. During the chronic phase, diagnosis is based on
positive results from testing with 2 different serologic tests, for
example, an enzyme-linked immunosorbent assay (ELISA) or
immunofluorescence assay (IFA), preferably using 2 different
antigen preparations [13, 14]. Published sensitivity and specificity of diagnostic tests range from 17% to 100% and 76% to
100% respectively, but these estimates must be interpreted cautiously due to geographic variation, heterogeneity in study designs, and the lack of a gold standard [15, 16]. Two drugs are
available for treatment, benznidazole and nifurtimox, although
guidelines for treatment are not well established. The BENEFIT
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trial, a randomized controlled trial of benznidazole vs placebo, showed no significant difference in clinical cardiac disease over 5.4 years of follow-up [17]. Antiparasitic treatment
is generally not used in advanced heart failure, and these patients may require implantation of cardiac devices or organ
transplantation [18].
In recent decades, the rate of emigration from Chagasendemic areas to the United States, Canada, Europe, Australia,
and Japan has increased markedly and has changed the epidemiology of Chagas disease in these countries [19]. It is estimated that 23 million immigrants from endemic regions live
in the United States and 300 000 of these persons are chronically infected by T. cruzi [20]. A screening program of >4000
Latin American immigrants residing in the Los Angeles area
found a Chagas disease prevalence of 1.24% [21]. The number
of T. cruzi–infected immigrants and the possibility of transmission by nonvectorial mechanisms have turned Chagas disease
into an emerging disease and a new public health problem in
destination countries. Physicians caring for migrant patients
need to become familiar with the diagnosis, complications, and
indications for treatment of Chagas disease. This manuscript reviews the experience managing 60 patients with Chagas disease
in hospitals throughout the New York City metropolitan area.
METHODS

We performed a retrospective study extracting demographic
and clinical information by manual chart review of patients
diagnosed with Chagas disease who were evaluated between
2005 and 2017 in major hospital systems in the New York City
metropolitan area, defined as the 5 New York City boroughs
and surrounding suburbs. Jacobi Medical Center (JMC) is a
hospital in the New York City Health and Hospital Corporation
and a major teaching facility of the Albert Einstein College of
Medicine. It is the main facility treating Chagas disease patients
through its Tropical Disease Clinic in the Bronx. Montefiore
Medical Center (MMC) in the Bronx is the site of a large heart
failure clinic and performs heart transplants, including transplants in Chagas disease patients with end-stage heart failure.
The Northwell-Hofstra University Medical Center is located on
Long Island in suburban New York City. Patients were referred
to the authors at these medical centers by physicians, family
members, or the New York Blood Center.
Patients were diagnosed with chronic Chagas disease on
the basis of serologic testing results. At the JMC Parasitology
Laboratory, the Hemagen Chagas’ Enzyme Immunoassay Kit
was used (Hemagen Diagnostics, Boston, MA, USA; sensitivity, 88%–92%; specificity, 99%–100%) [15]. At MMC and
Northwell, an ELISA was performed at a commercial lab (most
commonly the Hemagen Chagas Kit at Quest Diagnostics,
Inc.). At the Centers for Disease Control and Prevention
(CDC), reference confirmatory testing was performed with
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the commercial Chagatest ELISA recombinante, version 3.0
(Wiener Laboratorios, Argentina; sensitivity, 94%–97%; specificity, 97%–99%) [15], and an in-house IFA based on fixed
epimastigotes (sensitivity, 94%; specificity, 95%) [22] until 2014.
Thereafter, the in-house IFA was replaced with an in-house
trypomastigote excreted-secreted antigens (TESA) immunoblot
(sensitivity, 100%; specificity, 100%) [23]. When possible, family
members of patients were also screened. Heart transplant recipients were tested preemptively for T. cruzi DNA approximately
every 3 to 6 months after transplant to monitor for reactivation.
Specimens were sent to the CDC, which employed an algorithm
using 3 real-time polymerase chain reaction (PCR) assays with
different targets run in parallel (individual PCR assay: sensitivities, 6%–78%; specificities, 40%–100%) [24].
The decision to initiate treatment was consistent with the
practice of other experts and consensus groups [25, 26, 27]. In
general, treatment was offered to patients without the following
criteria: age >50 years, pregnancy, renal or hepatic dysfunction,
or advanced heart disease. Treatment decisions could be individualized and were at the discretion of the treating physician.
All heart transplant recipients with reactivation Chagas disease were treated. Whether the patient received benznidazole
or nifurtimox was based on drug availability per the CDC
Investigational New Drug (IND) protocol. Patients receiving
treatment were asked to follow up every 1–2 weeks to monitor
for adverse events. Asymptomatic patients not on treatment
were asked to follow up at least every 3–6 months, with closer
follow-up if symptoms developed.
Patient demographic and clinical information was stored
in a Microsoft Access (Seattle, WA, USA) database. This study
was approved by the Institutional Review Board of the Albert
Einstein College of Medicine and the Northwell-Hofstra
University Medical Center.
RESULTS
Epidemiology

Sixty patients were included in the study, 30 males and 30 females. The mean age at diagnosis (SD) was 47 (15.65) years,
ranging from 18 to 78 years. The plurality of patients (40%)
were from El Salvador, followed by Mexico, Ecuador, Bolivia,
Argentina, Brazil, Colombia, Guatemala, and Honduras
(Figure 1). Of these, 5 patients were first-generation Americans
born in the United States to immigrant parents, 3 from Bolivia
and 2 from Argentina. There were 3 patients who did not fulfill
all of the original criteria for confirmed infection but were nevertheless included because of compelling clinical findings compatible with Chagas disease and risk history of T. cruzi infection.
One was a 28-year-old woman with a positive ELISA at both
JMC and the CDC from El Salvador. The second patient was
a 78-year-old woman from the State of Minas Gerais in Brazil
who had a positive ELISA performed at Quest Laboratories and

Honduras (1)

Table 1. Clinical Manifestations of Chagas Disease (n = 60); Patients May
Report >1 Symptom so Numbers Sum to >100%

Guatemala (1)

Brazil (2)
Colombia (2)

Argentina (4)

Ei Salvador (24)

Bolivia (7)

No.

%

Asymptomatic

29

48

Cardiac

27

45

Heart failure

16

27

Chest pain

10

17

Palpitations

8

13

Dyspnea
Gastrointestinal
Constipation

Ecuador (7)

5

8

14

23

10

17

Dysphagia

6

10

Abdominal pain

5

8

Heartburn

1

2

Neurologic

1

2

Stroke

1

2

Headache

1

2

Mexico (12)

Figure 1. Country of origin of Chagas disease patients (n = 60). Five patients were
first-generation Americans born in the United States to Latin American immigrant
parents and are included in this figure under their parents’ country of origin.

clinical findings of mega-esophagus and a right bundle-branch
block (RBBB). The third patient was a 51-year-old woman born
in Ecuador who had a positive ELISA performed at JMC and
an RBBB.
Routine blood donor screening was the most common way
patients with Chagas disease were first identified (n = 21, 35%).
Seventeen patients were tested as part of evaluation for cardiac
disease. Ten patients were screened due to a family history of
Chagas disease. In 3 families, the index patient was detected
upon blood donation screening. In 1 family, the index patient
was among the 17 patients identified during evaluation of cardiac disease. Nine patients were diagnosed as part of screening
for endemic infectious diseases based on their country of origin. Two patients were tested due to a report of positive testing
as a child, and 1 due to complaint of gastrointestinal symptoms.

Out of 56 patients who had EKGs performed, 32 (57%) had
abnormal findings. The most common abnormalities were
RBBB (n = 12, 21%), sinus bradycardia (n = 12, 21%), and
T-wave changes (n = 12, 21%). There were 52 patients who
had an echocardiogram performed, of whom 28 (54%) were
abnormal. The most common echocardiogram abnormalities
were tricuspid regurgitation (n = 17, 33%) and ventricular wall
motion abnormalities, including hypokinesis, akinesis, and regional wall motion abnormalities (n = 16, 31%). A representative EKG and echocardiogram are shown in Figure 2. Of the 41
patients who had a chest x-ray performed, 12 (29%) had cardiomegaly. Twenty-three patients had gastrointestinal imaging
performed. The most common method of imaging was colonoscopy, followed by ultrasound, computed tomography, and
esophagogastroduodenoscopy. Upper gastrointestinal series
was performed in 4 patients. There was 1 patient with esophageal dilatation, 2 patients with small intestine dilatation, and 1
patient with megacolon. Both patients with esophageal dilatation and megacolon were from Brazil. Other findings included
gastritis (n = 4) and gall bladder thickening (n = 3). Table 2 describes specific EKG, echocardiogram, and chest x-ray findings
broken down by presence of symptoms.

Clinical Manifestations and Evaluation

Nearly half of patients (n = 29, 48%) were asymptomatic.
Twenty-seven (45%) patients had cardiac manifestations including heart failure and chest pain. Fourteen (23%) had gastrointestinal manifestations such as constipation, dysphagia, and
abdominal pain. Patients reporting gastrointestinal symptoms
were from El Salvador (n = 6), Ecuador (n = 3), Mexico (n = 2),
Bolivia (n = ), and Brazil (n = 1). One patient had a suspected
cardioembolic stroke from a cardiac apical aneurysm. Detailed
symptoms are described in Table 1. Fourteen out of 29 (48%)
asymptomatic patients had abnormal electrocardiogram (EKG)
or imaging findings.

Treatment

In total, 27 patients were treated with either benznidazole
or nifurtimox. Adverse effects were common, with 21 (78%)
patients reporting at least 1 symptom. Despite the presence
of adverse effects, 15 patients (71%) completed the full treatment course. Of the 17 patients treated with benznidazole,
5 (29%) did not complete therapy due to rash (n = 5) with
or without severe transaminitis (n = 2). Of the 10 patients
treated with nifurtimox, 2 (20%) did not complete therapy.
One patient developed nausea and abdominal pain, and 1 patient was lost to follow-up. Characteristics and adverse effects
Chagas in NYC Metropolitan Area • ofid • 3
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Figure 2. A, Representative electrocardiogram demonstrating sinus bradycardia, first-degree atrioventricular block, low voltage, T-wave changes, and right bundle
branch block. B, Representative transthoracic echocardiogram 4-chamber view demonstrating severe left ventricular dilatation and moderate right ventricular dilatation.
Abbreviations: LV, left ventricle; RV, right ventricle.

among patients receiving antitrypanosomal treatment are described in detail in Table 3.
Ten patients had advanced heart disease requiring a pacemaker (n = 1), implantable cardioverter defibrillator (n = 3), or
left ventricular assist device (LVAD) (n = 6). One LVAD recipient died while waiting for transplant, and the autopsy showed
cardiomyocyte hypertrophy and fibrosis that were attributed to
chronic Chagas disease. Six of the 10 patients received a heart
transplant. Of these, 2 patients had reactivation of T. cruzi infection after transplant, as determined by T. cruzi PCR positivity,
and were treated with benznidazole. One patient had graft rejection, and 1 had graft vasculopathy. Four patients were alive at
2, 2.5, 4, and 7 years post-transplant. One died due to postoperative complications, and 1 died from unrelated trauma.
DISCUSSION

To our knowledge, this is the largest case series describing the
clinical experience of Chagas disease in the United States. Over
a period of 12 years, we have cared for 60 patients. Most of the
patients were referred to the tropical medicine clinic at Jacobi
Medical Center, 1 of the few centers in New York City with experts in Chagas disease. Therefore the patients described in this
series likely represent a significant portion of patients who have
been diagnosed with Chagas disease in the region.
Similar to other studies from the United States, the most
common country of origin was El Salvador, representing
40% of patients. In a Los Angeles–based screening program,
Salvadorans were 6.2 times more likely than other Latin
American immigrants to test positive for Chagas disease [21].
Salvadorans also accounted for 72% of all Latin American patients who received benznidazole under the CDC IND protocol
4 • ofid • Zheng et al

[28]. In contrast, Bolivia is frequently the most common country
of origin in other nonendemic countries [29]. New York City
is home to nearly 1 million Latin American immigrants, who
account for the highest proportion (32%) of the city’s foreignborn individuals. Of these, the largest number were born in the
Dominican Republic, a country that is not endemic for Chagas
disease. The largest number of foreign-born individuals in New
York City from a Chagas-endemic country come from Mexico
(186 298), followed by Ecuador (137 791), Colombia (65 678), El
Salvador (32 903), and Honduras (28 552) [30, 31]. In our series,
5 patients were born in the United States to immigrant parents,
demonstrating the possibility of mother-to-child vertical transmission within nonendemic countries, although transmission
through other mechanisms due to shared epidemiologic risk
cannot be ruled out.
Nearly half of our patients were asymptomatic. Despite the
lack of overt symptoms, 48% of asymptomatic patients had
abnormal EKG or imaging findings, underscoring the need
for screening to identify patients before progression to clinical disease. Blood donation was the most common reason for
screening and would capture individuals who are infected but
asymptomatic. In addition, our experience highlights the importance of targeted screening in immigrants from endemic
countries, particularly if cardiac or gastrointestinal symptoms
are present. When a new diagnosis of Chagas disease is made,
family members who share the same exposure history or were
born to an infected mother should be tested as well [32]. Familybased screening has also been used in other medical centers to
effectively identify new cases, yielding a Chagas disease prevalence of 7.4% in a nonendemic setting [33] and as high as 42%
in endemic settings [34].

Table 2.

EKG, Echocardiogram, and Chest X-ray Findings in Chagas Disease; Patients May Have >1 Abnormality so Numbers Sum to >100%
EKG Findings
Asymptomatic

Symptomatic

Total

(n = 25)

(n = 31)

(n = 56)

%

Normal

16

8

24

43

Right bundle branch block

3

9

12

21

Sinus bradycardia

5

7

12

21

T wave changes

1

11

12

21

Premature atrial or ventricular contractions

2

9

11

20

Low voltage

1

6

7

13

Left axis deviation

0

6

6

11

First-degree AV block

0

5

5

9

Left bundle branch block

0

5

5

9

Atrial fibrillation

0

5

5

9

Prolonged QT

0

1

1

2

Left ventricular hypertrophy

1

0

1

2

Left atrial enlargement

0

1

1

2

Asymptomatic

Symptomatic

(n = 21)

(n = 31)

(n = 52)

%

16

8

24

46

Echocardiogram Findings

Normal

Total

Ventricular abnormalities
Wall motion abnormalities

0

16

16

31

Systolic dysfunction

0

13

13

25

Left ventricle dilatation

1

9

10

19

Left ventricle aneurysm

0

5

5

10

Right ventricle dilatation

1

3

4

8

Diastolic dysfunction

2

2

4

8

Left atrial dilatation/enlargement

2

9

11

21

Right atrial dilatation

1

2

3

6

Atrial septal aneurysm

1

1

2

4

Increased left atrial pressure

0

2

2

4

Atrial abnormalities

Valvular abnormalities
Tricuspid regurgitation

1

16

17

33

Mitral regurgitation

2

13

15

29
15

Aortic regurgitation

1

7

8

Pulmonary regurgitation

0

4

4

8

Mitral stenosis

0

1

1

2

Pulmonary hypertension

0

4

4

8

Pericardial effusion

0

4

4

8

Asymptomatic

Symptomatic

(n = 14)

(n = 27)

(n = 41)

%

1

11

12

29

Chest X-ray Findings

Cardiomegaly

Total

Abbreviations: AV, atrioventricular; EKG, electrocardiogram; QT, interval from start of the Q wave to the end of the T wave.

In keeping with expert opinion [25, 26, 27], we recommend
that the evaluation of Chagas disease include an EKG, echocardiogram, and chest x-ray. These studies may be able to detect subclinical cardiac involvement, such as sinus bradycardia,
RBBB, and wall motion abnormalities. Among our patients, 57%
had abnormal EKGs and 54% had abnormal echocardiograms,
compared with 31.5% and 5.6%, respectively, in a study of 485
Chagas disease patients in Spain [35]. Additionally, 27% of our
patients developed heart failure, compared with only 2.6% in

the Spanish study. The higher prevalence of cardiac disease and
abnormal cardiac evaluation in our study can be explained by
recruitment bias introduced from the fact that 1 of the treatment sites is a center for heart failure and transplantation.
Gastrointestinal disease is more common in patients from
the southern cone of South America (Brazil, Argentina, Bolivia,
Chile, and Paraguay) [36]. However, in our series patients
endorsing gastrointestinal symptoms were predominantly from
Mexico and Central America, possibly reflective of the fact
Chagas in NYC Metropolitan Area • ofid • 5

Table 3. Characteristics and Adverse Effects of Patients Receiving
Antitrypanosomal Therapy (n = 27)

Age, median
(range), y
Female, No. (%)

Benznidazole
(n = 17)

Nifurtimox
(n = 10)

Overall (n = 27)

36 (26–52)

31 (23–44)

36 (23–52)

9 (53)

4 (40)

13 (48)

Asymptomatic, No.
(%)

12 (71)

5 (50)

17 (63)

Completed treatment,
No. (%)

12 (71)

8 (80)

20 (74)

Experienced adverse
effects, No. (%)

13 (76)

8 (80)

21 (78)
13 (48)

Gastrointestinal

6 (35)

7 (70)

Abdominal pain

1 (6)

6 (60)

7 (26)

Anorexia

0 (0)

2 (20)

2 (7)

Heartburn

0 (0)

0 (0)

0 (0)

Nausea

2 (12)

4 (40)

6 (22)

Transaminitis
Dermatologic

4 (24)

0 (0)

4 (15)

7 (41)

2 (20)

9 (33)

Rash

7 (41)

2 (20)

9 (33)

Edema

2 (12)

0 (0)

2 (7)

Pruritis

0 (0)

1 (10)

1 (4)

3 (18)

5 (50)

8 (30)

Neurologic/
neuropsychiatric
Headache

0 (0)

4 (40)

4 (15)

Sleep disturbance

2 (12)

2 (20)

4 (15)

Memory loss

0 (0)

1 (10)

1 (4)

Anxiety

0 (0)

1 (10)

1 (4)

Peripheral neuropathy

2 (12)

1 (10)

3 (11)

Lightheadedness
Myalgias

0 (0)

2 (20)

2 (7)

0 (0)

2 (20)

2 (7)

Palpitations

0 (0)

1 (10)

1 (4)

Fatigue

0 (0)

1 (10)

1 (4)

Lost to follow-up

0 (0)

1 (10)

1 (4)

that subjective symptoms are nonspecific for Chagasic gastrointestinal disease. Imaging findings of dilated esophagus and
megacolon, findings more specific for Chagasic gastrointestinal disease, were present in 2 patients from Brazil. Therefore,
to evaluate for Chagasic gastrointestinal disease, we recommend that imaging be performed if any relevant complaints are
present.
When appropriate, patients were treated with either
benznidazole or nifurtimox based on drug availability through
the CDC. After the study period, benznidazole was FDA approved and, as of May 2018, has been commercially available
[28]. Benznidazole is now generally considered first-line therapy
due to better tolerability, although both benznidazole and
nifurtimox are associated with high rates of adverse effects [27].
Benznidazole most commonly produces dermatologic effects,
such as rash, edema, and itching. Gastrointestinal (eg, nausea,
abdominal pain, anorexia) and neurologic (eg, headache, neuropathy, insomnia) symptoms are also frequently reported [37,
38, 39]. Nifurtimox most commonly causes gastrointestinal and
6 • ofid • Zheng et al

neurologic symptoms; dermatologic symptoms are uncommon
[40, 41]. In our series, the prevalence of adverse effects was
high overall (78%), and the effects reported for benznidazole
and nifurtimox were similar to those described in the literature. The majority of adverse effects were minor and did not
require discontinuation of therapy. The discontinuation rate
was 29% among patients treated with benznidazole (compared
with 13%–30% reported in the literature) [17, 37, 38, 39] and
20% among patients treated with nifurtimox (compared with
20%–44% in the literature) [41, 42], although the number of
treated patients was small.
Patients with advanced heart disease were not offered
antiparasitic treatment, as treatment would not alter clinical
outcomes. In some cases, Chagasic heart disease was severely
advanced to the point of requiring implantable devices or transplantation. Limited evidence suggests that post-transplant
outcomes in Chagas disease patients are comparable to the outcomes of patients with heart failure from other causes [13], but
further evaluation is warranted. Similar to observations from
other US transplant centers [42], Chagas reactivation was a
significant concern in our heart transplant recipients. Risk of
reactivation is highest in the first 2 years post-transplant, and
highest for transplantation of hearts compared with other solid
organs [43]. In accordance with expert consensus, our transplant patients were monitored routinely with PCR, and those
with detectable parasitemia were treated. Prophylactic treatment is not recommended [44–45]. Donor-derived infection,
that is, transmission from a T. cruzi–infected donor to an uninfected recipient, was not present in this case series, though
it has been described in the United States [46–48]. Current
consensus guidelines recommend targeted screening of donors
born in endemic countries. Transplantation of kidney or liver
from a T. cruzi–infected donor is acceptable with informed consent, frequent parasitological monitoring post-transplant, and
immediate treatment if infection is detected. Heart transplants
from infected donors should be avoided [46].
In an era of increased migration, Chagas disease is emerging
as an important public health issue worldwide. Latin Americans
represent the largest foreign-born population in the New York
City metropolitan area and in the United States [30]. However,
the medical community in the United States has little awareness
or experience with Chagas disease [49–50]. Most infected persons are asymptomatic and go undiagnosed, but Chagas disease
can progress to severe heart disease and even death. Increased
awareness of risk factors and clinical manifestations of Chagas
disease is necessary to identify and treat patients early.
Limitations

This is a retrospective study that describes patients limited
to the practice of the authors and may not be representative
of other settings. Additionally, we describe only patients who
presented to our hospitals, including some referred by family

members, private physicians, and the New York Blood Center,
which excludes those with limited access to care. One patient
was lost to follow-up. Symptoms reported or test results may
not be related to Chagas disease, and tests may have been performed for reasons other than evaluation of Chagas disease.
Due to the fact that patients were identified by referral, we are
unable to determine prevalence in our hospitals or communities. A prior study found the prevalence of Chagas disease to
be 0.008% among the New York City metropolitan area blood
donor population, which was the most common source of referral for our patients [51].
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